Upregulation of the ErbB family by EZH2 in hepatocellular carcinoma confers resistance to FGFR inhibitor

PURPOSE: Hepatocellular carcinoma (HCC), the most common manifestation of liver cancer, is one of the leading causes of cancer-related mortality worldwide with limited treatment options. Infigratinib, a pan-FGFR inhibitor, has shown a potent antitumour effect in HCC. However, drug resistance is ofte...

Descripción completa

Detalles Bibliográficos
Autores principales: Prawira, Aldo, Le, Thi Bich Uyen, Ho, Rebecca Zhi Wen, Huynh, Hung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article – Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397639/
https://www.ncbi.nlm.nih.gov/pubmed/34156519
http://dx.doi.org/10.1007/s00432-021-03703-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397639/
https://www.ncbi.nlm.nih.gov/pubmed/34156519
http://dx.doi.org/10.1007/s00432-021-03703-6

Ejemplares similares